Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study
Sanz Segura, Patricia (Universidad de Zaragoza) ; Gomollón, Fernando (Universidad de Zaragoza) ; Casas, Diego (Universidad de Zaragoza) ; Iborra, Marisa ; Vela, Milagros ; Fernández-Clotet, Agnès ; Muñoz, Roser ; García de la Filia, Irene ; García Prada, María ; Ferrer Rosique, Juan Ángel ; García, María José ; de Francisco, Ruth ; Arias, Lara ; Barrio, Jesús ; Guerra, Iván ; Ponferrada, Ángel ; Gisbert, Javier P. ; Carrillo-Palau, Marta ; Calvet, Xavier ; Márquez-Mosquera, Lucía ; Gros, Beatriz ; Cañete, Fiorella ; Monfort, David ; Madrigal Domínguez, Rosa Eva ; Roncero, Óscar ; Laredo, Viviana ; Montoro, Miguel (Universidad de Zaragoza) ; Muñoz, Carmen ; López-Cauce, Beatriz ; Lorente, Rufo ; Fuentes Coronel, Ana ; Vega, Pablo ; Martín, Dolores ; Peña, Elena ; Varela, Pilar ; Olivares, Sonsoles ; Pajares, Ramón ; Lucendo, Alfredo J. ; Sesé, Eva ; Botella Mateu, Belén ; Nos, Pilar ; Domènech, Eugeni ; García-López, Santiago (Universidad de Zaragoza)
Resumen: Background
some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible.
Aims
to assess the management of antiTNF-IP in IBD, and its impact in both diseases.
Methods
patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks.
Results
234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse.
Conclusion
skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies.
Idioma: Inglés
DOI: 10.1016/j.dld.2024.05.021
Año: 2024
Publicado en: DIGESTIVE AND LIVER DISEASE 56, 12 (2024), 2060-2068
ISSN: 1590-8658
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Fecha de embargo : 2025-06-15
Exportado de SIDERAL (2024-12-20-12:05:35)
Visitas y descargas
some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible.
Aims
to assess the management of antiTNF-IP in IBD, and its impact in both diseases.
Methods
patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks.
Results
234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse.
Conclusion
skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies.
Idioma: Inglés
DOI: 10.1016/j.dld.2024.05.021
Año: 2024
Publicado en: DIGESTIVE AND LIVER DISEASE 56, 12 (2024), 2060-2068
ISSN: 1590-8658
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Fecha de embargo : 2025-06-15
Exportado de SIDERAL (2024-12-20-12:05:35)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Medicina
Record created 2024-08-22, last modified 2024-12-20